《新股表現》騰盛博藥(02137.HK)暗盤高開10%報24.5元
根據輝立交易平臺顯示,明天掛牌的騰盛博藥-B(02137.HK)暗盤高開10%報24.5元,高低暫見26.5元/21元,現造22.3元,較上市價22.25元,高0.2%,成交370萬股。
騰盛是一家總部位於中國及美國仍未有盈利的生物科技公司,致力於促進中國及全球就重大傳染病如乙型肝炎病毒(HBV)、人類免疫缺陷病毒(HIV)、多重耐藥(MDR)或廣泛耐藥性(XDR)革蘭氏陰性菌感染,以及其他具有重大公共衛生負擔的疾病如中樞神經系統(CNS)疾病的療法。
是次在港上市共發售1.1158億股,並已引入11個機構爲基石投資者,合共認購5,302.75萬股;10%公開發售獲291倍超購,已啓動回撥機制佔比曾至50%,認購一手中籤率僅5%;股份以招股範圍(21-22.25元)上限定價,料集資淨額約23.34億元,主要用於HBV功能性治癒項目、用於爲BRII-778和BRII-732正在進行及計劃的臨牀試驗及登記備案準備提供資金、用於MDR/XDR革蘭氏陰性菌感染項目、用於爲BRII-296正在進行及計劃的臨牀試驗及登記備案準備提供資金等。上市聯席保薦人分別爲大摩及瑞銀。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.